**Principal Investigator**

|  |  |  |  |
| --- | --- | --- | --- |
| Name & email | Position | Department | Division |
|  |  |  |  |

**Co-Investigator**

|  |  |  |  |
| --- | --- | --- | --- |
| Name & email | Position | Department | Division |
|  |  |  |  |

**Project Title**

|  |
| --- |
|  |

**Research Area (please tick all that apply)**

|  |  |
| --- | --- |
| Bioscience for health |  |
| Infection/Immunity/Inflammation/AMR |  |
| Vaccine Science |  |
| Rare diseases |  |
| Neuroscience  |  |
| Diabetes |  |
| Oncology |  |
| Cell and Gene Therapies |  |
| Mental Health |  |
| Endocrinology |  |
| AI/Data Science for health |  |
| Physical sciences linked to medical research |  |
| Related to COVID-19 |  |
| Other (please describe) |  |

**Administrative Contact for Award** *(Departmental research facilitator, manager, administrator or finance officer who can facilitate award set up through IRAMS and X5).*

|  |  |
| --- | --- |
| Name, position and contact details of administrative contact: |  |

**Abstract** *(max. 250 words)*

|  |
| --- |
|  |

**Non-confidential lay summary** *(This information could be shared with external agencies eg. funders and potential industry partners if deemed within the best interest of the PI.Please Include a description of your innovation and its impact, who the potential partners and/or end user could be, the competitive advantage, how the funding will be used to reach a critical milestone– max 250 word))*

|  |
| --- |
|  |

I am happy for this summary to be shared with selected potential industry collaborators and/or funders [ ] N. [ ] Y.

**Intellectual Property**

|  |
| --- |
| ***Brief outline of existing and expected IP from this proposal****. Please consult with Oxford University Innovations (contact details at end of document) to discuss all intellectual property matters.* |
| Do you have any patents /IP in place or submitted that covers this work? | [ ] N. [ ] Y. Please give brief details:      |
| Do you anticipate that work proposed here will give rise to any intellectual property? | [ ] N. [ ] Y. Please give brief details:      |
| Do any organisations other than Oxford, have any rights to the work being proposed here *(e.g. through commercial sponsorship, or grant funding)?* | [ ] N. [ ] Y. Please give brief details:      |
| Do you need to access background IP/patents, materials, data or other resources held by anyone else for this work (*e.g. using a technique/ discoveries patented by another group, or materials, data or equipment provided under an agreement)?* | [ ]  N. [ ]  Y. Please give brief details:       |
| Have Oxford University Innovations been engaged in discussions around the proposed research?  | [ ]  N. [ ]  Y. Please give brief details of Licensing and Ventures Manager engaged with project:       |

**Ethics**

|  |  |
| --- | --- |
| [ ]  Not required  | Please give reason *(e.g. does not involve human material):*      |
| [ ]  Application in progress  | Please state status:      |
| [ ]  Ethics obtained | Please give relevant ethics committee project title and reference number:      |

**Novo Nordisk Innovation Fund**

| *The Novo Nordisk Innovation Fund seeks proposals addressing unmet patient need in diabetes and other cardiometabolic disease (obesity, NASH, atherosclerosis, heart failure and chronic kidney disease) as well as within the field of rare endocrine and rare non-malignant blood diseases. Please contact the TRO for further information* *translationalresearchoffice@medsci.ox.ac.uk**.* |
| --- |
| Do you want your proposal to be considered by Novo Nordisk for funding through the ‘Innovation Fund’? [ ] Y [ ] NDoes your proposal fit with the identified Novo Nordisk Priority Areas? [ ] Y [ ] NHave you identified a Novo Nordisk Collaborator? [ ] Y [ ] N ***Please give details:*** |

**Oxford Biomedica Innovation Fund**

| *The Oxford Biomedica Innovation Fund seeks proposals addressing the development of platform technologies such as lentivirus vectors, AAV, and lipid nanoparticles. Priority areas also include therapeutic areas in cell and gene therapies in Oncology, liver and neurology. Please contact the TRO for further information* *translationalresearchoffice@medsci.ox.ac.uk**.* |
| --- |
| Do you want your proposal to be considered by Oxford Biomedica for funding through the ‘Innovation Fund’? [ ] Y [ ] NDoes your proposal fit with the identified Oxford Biomedica Priority Areas? [ ] Y [ ] NHave you identified an Oxford Biomedica Collaborator? [ ] Y [ ] N ***Please give details:*** |

**CRUK Co-Fund**

| *The CRUK co-Fund seeks proposals that have been previously or are currently funded by CRUK and fall within the Oncology remit. Please contact the TRO for further information* *translationalresearchoffice@medsci.ox.ac.uk**.* |
| --- |
| Have you previously received CRUK funding for research directly related to this application? [ ] Y [ ] NHave you been shortlisted through the EOI stage by CRUK? [ ] Y [ ] N ***Please give details:*** |

**University Challenge Seed Fund**

|  |  |
| --- | --- |
| Have you applied for UCSF funding?  | [ ] Y [ ] N  |
| Have you already been awarded funding through UCSF?Please state funding volume (£)?  | [ ] Y [ ] N **Award Made: £**  |

**Case for support (4 pages max)**

**Project Description and Realisation** *(*including project objectives and proposed outcomes, information about proposed development milestones, a timeline for your project, aligning with milestones to demonstrate that these are realistic both in terms of the objectives set and the time necessary to achieve them risks mitigation measures and potential next steps following completion of the project to include, for example, sources of follow on funding, plans for commercialisation – 2 pages max*).*

|  |
| --- |
|  |

Which follow-on funding streams would be most appropriate for your project? [ ]  MRC DPFS [ ]  NIHR i4i [ ]  BHF TA [ ] CRUK MPA [ ]  Other

**Competitiveness of the approach** (including a discussion around market competition, will the proposed research offer significant advantages over current methodologies, which are the main competitive solutions, academic and industry solutions should be considered for the discussion, 1/2 pages max)

|  |
| --- |
|  |

Have you considered, or do you have the need, to receive support for market research and identify commercial opportunities? [ ] Y [ ] N. If you have ticked yes, please note that MLSTF can fund market research or business development support as part of the proposal.

**Industry engagement** (details of any development of industrial engagement in your project and plans to advance this, ½ pages max)

|  |
| --- |
|  |

**Intellectual property and regulatory management** (are third parties involved and how will IP be managed with respect to these collaborators? Has the research in this proposal been funded in the past by a third party? How will you manage background and foreground IP? Have you consulted all relevant agreements in advance of submitting your application (e.g. MICA)? Have you assessed relevant regulatory requirements?)

|  |
| --- |
|  |

**Justification for support** (how your proposal is aligned with the remit and objectives of the fund)

|  |
| --- |
|  |

**Sources of matched funding**

|  |
| --- |
|  |

|  |
| --- |
| **Once completed please attach this form alongside CVs (one page max. each) for all named applicants and a copy of the X5 costing (combined into a single pdf document) to the IRAMS application by 12:00 on Friday 22nd October 2021.** |